Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8295MR)

This product GTTS-WQ8295MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8295MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3604MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ1150MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ13626MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ2249MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ2950MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ4647MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ15676MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ3231MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-113
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW